Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Adults with stable, moderate to severe hidradenitis suppurativa

• Negative Chest X-ray and PPD test at Screening. If participant has had a past ulcerative reaction to PPD placement and/or chest X-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy.

• Ability to administer subcutaneous injections

• General good health otherwise

Exclusion Criteria:

• Prior anti-TNF therapy

• Unstable antibiotic therapy for HS

• Required medication washouts for other HS treatments

• Prior exposure to Tysabri® (natalizumab);

• Recent infection requiring treatment

• Significant medical events or conditions that may put patients at risk for participation

• Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;

• History of cancer, except successfully treated skin cancer

• Recent history of drug or alcohol abuse